PHGE: BiomX Ltd Growth-Adjusted Market Cap to Net Income

Symbol and logo of brand BiomX Ltd (PHGE)

BiomX Inc. (PHGE) develops viral cocktails to eliminate pathogens without harming the microbiome, strengthening its position through patents and R&D assets. The undervalued "rockets" filter based on PEG visualizes the balance between market capitalization and earnings, where the 0.00 mark reflects the latest data. High pricing power in the resistance-fighting segment renders the demand for personalized phages inelastic.

PHGE (biomx.com) PEG Multiple history from 07/04/2022 to 09/11/2026

Analytical breakdowns for BiomX Inc. (PHGE)

- share price and consensus valuation forecast:
Price Performance Chart biomx.com|PHGE - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization BiomX Ltd|PHGE - Total Company Value
- company book value details:
Equity per Share BiomX|PHGE - Book Capitalization|Market Capitalization to Net Assets biomx.com|PHGE - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital BiomX Inc.|PHGE - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio biomx.com|PHGE - Company Total Debt|Debt to Book Capital BiomX Ltd|PHGE - Company Long-Term Debts|Short-Term Debt Volume BiomX|Immediate Liquidity biomx.com
- net income and valuation multiples indicators:
PHGE - Company Net Income|Net Profit Forecast BiomX Inc.|PHGE - Price to Earnings Ratio|Market Cap to Projected Earnings biomx.com|PHGE - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BiomX Ltd|PHGE - Operating profit EBITDA|Net earnings per share for the last four quarters BiomX|PHGE - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomx.com|PHGE - Earnings per share growth in current year|Expected earnings per share growth for next year BiomX Inc.
Summary company analytics:BiomX Inc
Mass-produced product of BiomX

BiomX Inc. automates bacteriophage bioscreening using robotic systems to combat pathogens. An analysis of the P/E balance and growth ratio compares the market value of shares with net profit dynamics. This metric determines the fairness of the business valuation by isolating the cost per unit of earnings growth. A value below one signals that the asset is undervalued relative to its expansion. This allows for the identification of capitalization growth potential amid technological scaling.

Competing companies

SMMT (Summit Therapeutics plc) - Growth-Adjusted Payback Ratio|PEG Multiple MRNA (Moderna Corp)|Growth-Adjusted Market Cap to Net Income SutroVax (PCVX)|TARS - Price/Earnings to Growth Ratio|CRMD (cormedix.com) - Growth-Adjusted P/E Ratio|MCRB: PEG Multiple|Market Cap to Earnings and Growth Ratio SPRO (Spero Therapeutics Inc)|SCYX (SCYNEXIS Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate AN2 Bio ANTX|PEG Multiple PYPD|Price/Earnings to Growth Multiple ysbiopharm.com LSB|Iterum Therapeutics - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SNGX (Soligenix Inc)|60 Degrees Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Oragenics Inc. OGEN|OpGen, Inc. (OPGN) - Price/Earnings to Growth Ratio